Biogen Income After Taxes 2010-2024 | BIIB

Biogen income after taxes for the twelve months ending September 30, 2024 was $1.614B, a 10.42% increase year-over-year.

  • Biogen annual income after taxes for 2023 was $1.162B, a 60.75% decline from 2022.
  • Biogen annual income after taxes for 2022 was $2.959B, a 74.81% increase from 2021.
  • Biogen annual income after taxes for 2021 was $1.693B, a 58.26% decline from 2020.

Biogen Income After Taxes 2010-2024 | BIIB

  • Biogen annual income after taxes for 2023 was $1.162B, a 60.75% decline from 2022.
  • Biogen annual income after taxes for 2022 was $2.959B, a 74.81% increase from 2021.
  • Biogen annual income after taxes for 2021 was $1.693B, a 58.26% decline from 2020.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$145.5B
Vertex Pharmaceuticals (VRTX)$119.4B
Gilead Sciences (GILD)$114.5B
Bristol Myers Squibb (BMY)$113.1B
CSL (CSLLY)$84.9B
Regeneron Pharmaceuticals (REGN)$80.4B
GSK (GSK)$70.4B
Argenex SE (ARGX)$36.7B
Alnylam Pharmaceuticals (ALNY)$31.7B
BioNTech SE (BNTX)$28.6B
Illumina (ILMN)$22.8B
BeiGene (BGNE)$17.5B
Moderna (MRNA)$16.1B
Genmab (GMAB)$13.3B
Incyte (INCY)$13.2B
Insmed (INSM)$12.8B
BioMarin Pharmaceutical (BMRN)$12.6B
Bio-Techne Corp (TECH)$12B
Sarepta Therapeutics (SRPT)$11.8B
Exact Sciences (EXAS)$11.3B
Vaxcyte (PCVX)$10.9B
QIAGEN (QGEN)$10.4B
Exelixis (EXEL)$10B
Bio-Rad Laboratories (BIO.B)$9.4B
Intra-Cellular Therapies (ITCI)$8.8B
Repligen (RGEN)$8.8B
Roivant Sciences (ROIV)$8.6B
Ascendis Pharma (ASND)$7.9B
Revolution Medicines (RVMD)$7.6B
Jazz Pharmaceuticals (JAZZ)$7.4B